
UCB has partnered with Synosia Therapeutics to develop two of the Swiss firm’s compounds for Parkinson’s disease. Basel-based Synosia has …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

